161 related articles for article (PubMed ID: 38057403)
1. Patients with uncommon EGFR mutations also benefit from first-line osimertinib.
Romero D
Nat Rev Clin Oncol; 2024 Feb; 21(2):84. PubMed ID: 38057403
[No Abstract] [Full Text] [Related]
2. Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
Wang VE; Gainor JF
JAMA Oncol; 2024 Jan; 10(1):52-53. PubMed ID: 37991771
[No Abstract] [Full Text] [Related]
3. Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
Lu K; Woodward BD; Boys J; Onaitis M; Husain H
Clin Lung Cancer; 2024 Jan; 25(1):e58-e61. PubMed ID: 37852849
[No Abstract] [Full Text] [Related]
4. Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Lim SM; Lee JB; Cho BC
J Thorac Oncol; 2024 Mar; 19(3):376-379. PubMed ID: 38453325
[No Abstract] [Full Text] [Related]
5. Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC.
Chen LN; Lee ATM; Nagasaka M; Ou SI
J Thorac Oncol; 2024 Mar; 19(3):380-384. PubMed ID: 38453326
[No Abstract] [Full Text] [Related]
6. Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Moik F; Riedl JM; Ay C
Ann Oncol; 2024 Mar; 35(3):327. PubMed ID: 38092622
[No Abstract] [Full Text] [Related]
7. Acquired Resistance to Osimertinib in
Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
van Waalwijk van Doorn-Khosrovani SB; Badrising SK; Burgers S
N Engl J Med; 2024 Feb; 390(5):478. PubMed ID: 38294983
[No Abstract] [Full Text] [Related]
9. Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C.
Passaro A; Wang J; Shah S; Bauml JM; Campelo RG; Cho BC
Ann Oncol; 2024 Mar; 35(3):328-329. PubMed ID: 38029840
[No Abstract] [Full Text] [Related]
10. Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
Planchard D; Jänne PA; Kobayashi K
N Engl J Med; 2024 Feb; 390(5):478-479. PubMed ID: 38294984
[No Abstract] [Full Text] [Related]
11. Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib.
Bennett P; Finall A; Medeiros F; Gerrard G; Taniere P
Eur J Cancer; 2022 Oct; 174():315-317. PubMed ID: 35934607
[No Abstract] [Full Text] [Related]
12. Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.
Ikari T; Sakakibara-Konishi J; Yamamoto G; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
Clin Lung Cancer; 2019 Jul; 20(4):e531-e533. PubMed ID: 31164318
[No Abstract] [Full Text] [Related]
13. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.
Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y;
JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib-related liver injury with successful osimertinib rechallenge: A case report.
Cheng YL; Chang WK; Yen H; Peng YJ; Chang WC; Chang PY
Thorac Cancer; 2022 Aug; 13(15):2271-2274. PubMed ID: 35793806
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib Versus Durvalumab Versus Observation After Chemoradiation in Unresectable EGFR-Mutant NSCLC.
Zhao B; Yao L; Ma W
J Thorac Oncol; 2024 May; 19(5):e5-e6. PubMed ID: 38719426
[No Abstract] [Full Text] [Related]
16. Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.
Jelinek MJ; Armstrong SA; Patel JD; Subramaniam DS
Clin Lung Cancer; 2019 Nov; 20(6):e597-e600. PubMed ID: 31542322
[No Abstract] [Full Text] [Related]
17. Lazarus effect in a patient initially empirically treated with osimertinib for
Bhatia S; Cortez MG; Lessans S; Iams WT
Oncotarget; 2024 Jan; 15():27-30. PubMed ID: 38227738
[TBL] [Abstract][Full Text] [Related]
18. Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Bonanno L; Dómine M; Poole L; Bolanos A; Rukazenkov Y; Wu YL
Target Oncol; 2024 Mar; 19(2):131-134. PubMed ID: 38466534
[TBL] [Abstract][Full Text] [Related]
19. Comment on "Consolidation Osimertinib Versus Durvalumab following Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC".
Chen CY; Wang GS; Wei JC
J Thorac Oncol; 2024 May; 19(5):e6-e7. PubMed ID: 38719427
[No Abstract] [Full Text] [Related]
20. Response to trametinib in a nonsmall cell lung cancer patient with osimertinib resistance harboring GNAS R201C and R201H mutations: a case report.
Lv Y; Zhou C; Chen Z; Zhao X; Sun Y; Li J; Gong Z; Zhang D; Huang H
Anticancer Drugs; 2022 Oct; 33(9):966-969. PubMed ID: 35946511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
